Drug recall · November 30, 2016
BuPROPion Hydrochloride Extended-Release Tablets recall
Why: Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA inc. Pennington, NJ 08534, NDC 68382-354-05
- Lots / codes
Lot #: MR3365, Exp. Feb 17
- Quantity
- 2,472 units
- Company
- Zydus Pharmaceuticals USA Inc, Pennington, NJ
- Distribution
- Nationwide
- Initiated
- August 3, 2016 · Voluntary: Firm initiated
- Classified
- November 22, 2016
- Reported
- November 30, 2016
- Ended
- July 12, 2018
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupropion
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.